In recent years, the world has experienced a significant shortage of blood-derived products such as Human Albumin or Human Immunoglobulin, which are derived from the plasma of healthy human donors or are related to blood or its components.
The scarcity of these materials and the demand for treating various diseases and medical conditions have led many pharmaceutical companies to face serious problems in maintaining a constant supply for the production of their essential products and treatments.
Despite the challenges in the market, North Life Pharma, which has certainly noticed this significant decline in human plasma stocks, has managed to remain a reliable supplier of blood-derived products. This is largely due to the strategic alliances it has established with several industry-leading manufacturers, partnerships that have allowed North Life Pharma to continue supplying its product portfolio to its customers under the same terms and conditions as always, including delivery times and competitive prices, as in previous years.
Proof of this is that, during the first quarter of 2023, North Life Pharma supplied more than 10,000 units of Human Albumin to its customers around the world. This achievement demonstrates the company’s commitment to ensuring that customers who depend on these vital products have access to them in a timely and reliable manner.
North Life Pharma products are manufactured in certified manufacturing plants that comply with the Good Manufacturing Practices (GMP) established by WHO, which in some cases also have GMP issued by other countries considered of high surveillance by WHO. Tests and evaluations are carried out at each stage to guarantee the effectiveness of the finished product.
The importance of blood products
Blood-derived products are crucial in the therapy and prevention of various diseases. These products are obtained from the plasma of healthy human donors and are used in the production of different treatments to enhance patients’ quality of life and address a wide range of medical conditions such as blood loss, coagulation disorders, and immunodeficiencies.
According to the World Health Organization (WHO), the availability and safety of blood-derived products are essential in modern medicine, and their use is governed by strict standards of quality and safety to ensure treatment effectiveness and avoid risks to patients.
North Life Pharma recognizes the significance of these treatments for patients’ quality of life and is committed to ensuring their availability despite current challenges. In fact, despite the global shortage, North Life Pharma has proven to be a reliable supplier of blood-derived products, with sufficient capacity to meet demand and maintain its position as a trusted provider in the pharmaceutical industry.